STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Vir Biotechnology insider filing: 46,696 shares sold under Rule 10b5-1

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology (VIR): insider share sales disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales of VIR common stock pursuant to a Rule 10b5‑1 plan entered on September 3, 2025.

On October 24, 2025, 46,696 shares were sold at a weighted average price of $5.9595, with trades ranging from $5.92 to $6.0212. On October 27, 2025, 66,403 shares were sold at a weighted average price of $6.0477, with trades ranging from $5.93 to $6.18. Following these transactions, 14,598,536 shares were beneficially owned on an indirect basis through SVF Endurance, as noted in the filing’s footnotes regarding SoftBank Vision Fund’s management structure.

Positive

  • None.

Negative

  • None.
Insider SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P., SB INVESTMENT ADVISERS (UK) LTD
Role 10% Owner | 10% Owner | 10% Owner
Sold 113,099 shs ($680K)
Type Security Shares Price Value
Sale Common Stock 66,403 $6.0477 $402K
Sale Common Stock 46,696 $5.9595 $278K
Holdings After Transaction: Common Stock — 14,598,536 shares (Indirect, See footnote)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.0212. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd
(Last) (First) (Middle)
C/O WALKERS CORP LTD.,190 ELGIN AVENUE
(Street)
GEORGE TOWN, E9 KY1-9008
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/24/2025 S(1) 46,696 D $5.9595(2) 14,664,939 I See footnote(3)
Common Stock 10/27/2025 S(1) 66,403 D $6.0477(4) 14,598,536 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd
(Last) (First) (Middle)
C/O WALKERS CORP LTD.,190 ELGIN AVENUE
(Street)
GEORGE TOWN, E9 KY1-9008
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SOFTBANK VISION FUND (AIV M1) L.P.
(Last) (First) (Middle)
1521 CONCORD PIKE
(Street)
WILMINGTON, DE 19803
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SB INVESTMENT ADVISERS (UK) LTD
(Last) (First) (Middle)
69 GROSVENOR STREET
(Street)
LONDON, X0 W1K 3JP
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.0212. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director 10/28/2025
SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel 10/28/2025
SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did VIR insiders report in this Form 4 filing?

SVF Endurance (Cayman) Limited reported open‑market sales of Vir Biotechnology common stock under a Rule 10b5‑1 plan.

How many VIR shares were sold and on which dates?

46,696 shares were sold on October 24, 2025, and 66,403 shares were sold on October 27, 2025.

What were the weighted average sale prices for the transactions?

Weighted averages were $5.9595 on October 24, 2025, and $6.0477 on October 27, 2025.

What were the price ranges for the sales?

On October 24, trades ranged from $5.92 to $6.0212; on October 27, trades ranged from $5.93 to $6.18.

How many VIR shares were beneficially owned after the reported sales?

14,598,536 shares were beneficially owned on an indirect basis following the transactions.

Was a Rule 10b5-1 trading plan used?

Yes. The sales were effected pursuant to a Rule 10b5‑1 plan entered on September 3, 2025.